Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase

Authors

John O. Mascarenhas, Icahn School of Medicine at Mount Sinai
Camille N. Abboud, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

2020

Volume

4

Issue

20

First Page

5246

Last Page

5256

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2020002119

Rights and Permissions

John O. Mascarenhas, Raajit K. Rampal, Heidi E. Kosiorek, Rupali Bhave, Elizabeth Hexner, Eunice S. Wang, Aaron Gerds, Camille N. Abboud, Marina Kremyanskaya, Dimitry Berenzon, Olatoyosi Odenike, Noushin Farnoud, Aishwarya Krishnan, Rona Singer Weinberg, Erin McGovern, Mohamed E. Salama, Vesna Najfeld, Juan S. Medina-Martinez, Juan E. Arango Ossa, Max F. Levine, Yangyu Zhou, Lonette Sandy, Mark L. Heaney, Ross L. Levine, Ruben A. Mesa, Amylou C. Dueck, Ronald Hoffman; Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv 2020; 4 (20): 5246–5256. doi: https://doi.org/10.1182/bloodadvances.2020002119

Recommended Citation

Mascarenhas, John O.; Abboud, Camille N.; and al., et, "Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase." Blood Advances. 4, 20. 5246 - 5256. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9847